-
1.发明授权PHARMACEUTICAL FORMULATION IN THE FORM OF BILAYERED TABLETS COMPRISING HMG-COA REDUCTASE INHIBITOR AND IRBESARTAN 有权HMG-COA还原酶抑制剂和IRBESARTAN双层片剂的药物制剂
公开(公告)号：EP2568972B1
公开(公告)日：2017-08-02
申请号：EP11780838.6
申请日：2011-05-13
发明人： KIM, Yong Il , NA, Young Jun , KIM, Min Jung , KIM, Young-Hun , PARK, Jae Hyun , WOO, Jong Soo
CPC分类号： A61K31/40 , A61K9/1611 , A61K9/1652 , A61K9/2009 , A61K9/2054 , A61K9/209 , A61K31/415 , A61K45/06 , A61K2300/00
-
2.发明公开PHARMACEUTICAL FORMULATION IN THE FORM OF BILAYERED TABLETS COMPRISING HMG-COA REDUCTASE INHIBITOR AND IRBESARTAN 有权药物制剂片剂具有两层HMG-CoA还原酶与厄贝沙坦形式
公开(公告)号：EP2568972A2
公开(公告)日：2013-03-20
申请号：EP11780838.6
申请日：2011-05-13
发明人： KIM, Yong Il , NA, Young Jun , KIM, Min Jung , KIM, Young-Hun , PARK, Jae Hyun , WOO, Jong Soo
CPC分类号： A61K31/40 , A61K9/1611 , A61K9/1652 , A61K9/2009 , A61K9/2054 , A61K9/209 , A61K31/415 , A61K45/06 , A61K2300/00
摘要： Provided is a pharmaceutical formulation in the form of bilayered tablets consisting of a first layer containing irbesartan or pharmaceutically acceptable salts thereof and a second layer containing an HMG-CoA reductase inhibitor and a basic additive, which can improve the dissolution rate and stability of irbesartan and an HMG-CoA reductase inhibitor to enhance the bioavailability of the drug compared to conventional complex formulations and to minimize the generation of the related compounds, thereby being effectively used as a stable and superior therapeutic agent for hypertension and hypercholesterolemia.
-
3.发明公开COMPLEX FORMULATION COMPRISING ASPIRIN COATED WITH BARRIER CONTAINING HYDROPHOBIC ADDITIVE, AND HMG-COA REDUCTASE INHIBITOR 审中-公开与阿司匹林的复合制剂与疏水性添加剂锁是BESCHICHTETET和HMG-CoA还原酶
公开(公告)号：EP2531199A2
公开(公告)日：2012-12-12
申请号：EP11739961.8
申请日：2011-01-26
发明人： WOO, Jong Soo , PARK, Jae Hyun , KIM, Yong Il , NA, Young Jun , CHOI, Jun Young , LEE, Yun Ah
IPC分类号： A61K31/60 , A61K31/505 , A61K31/40 , A61P9/00
CPC分类号： A61K31/40 , A61K9/1652 , A61K9/5063 , A61K9/5084 , A61K31/505 , A61K31/616 , A61K45/06 , A61K2300/00
摘要： Provided is a complex formulation for the prevention or treatment of cardiovascular diseases, comprising: a) aspirin coated with a barrier containing a hydrophobic additive; and b) an HMG-CoA reductase inhibitor, which has improved storage stability by preventing the deterioration in the stability of HMG-CoA reductase which is caused by salicylic acid, thereby being used in the treatment of hypertension and hypercholesterolemia.
-
公开(公告)号：EP2531180A2
公开(公告)日：2012-12-12
申请号：EP11737251.6
申请日：2011-01-18
发明人： WOO, Jong Soo , PARK, Jae Hyun , KIM, Yong Il , NA, Young Jun , KIM, Min Jung , LEE, Yun Ah
IPC分类号： A61K9/24 , A61K9/30 , A61K9/22 , A61K31/495
CPC分类号： A61K31/495 , A61K9/209 , A61K31/137 , A61K2300/00
摘要： An oral complex composition which comprises (i) a core comprising a swellable hydrogel-forming agent and pseudoephedrine, or a pharmaceutically acceptable salt thereof; (ii) a first coating layer encasing the core which comprises a water-soluble substance; and (iii) a second coating layer deposited on the first coating layer which comprises levocetirizine or a pharmaceutically acceptable salt thereof together with polyvinylalcohol, povidone, polyvinylalcohol-polyethyleneglycol graft copolymer or a mixture thereof, has an improved levocetirizine releasing rate and does not show a delayed release behavior even after a long storage period. Accordingly, the inventive oral complex composition is useful for treating perennial or seasonal allergic diseases including nasal obstruction, sneezing, and rhinorrhea.
-
5.发明授权
公开(公告)号：EP2531180B1
公开(公告)日：2017-06-21
申请号：EP11737251.6
申请日：2011-01-18
发明人： WOO, Jong Soo , PARK, Jae Hyun , KIM, Yong Il , NA, Young Jun , KIM, Min Jung , LEE, Yun Ah
IPC分类号： A61K9/24 , A61K9/30 , A61K9/22 , A61K31/495 , A61K31/137
CPC分类号： A61K31/495 , A61K9/209 , A61K31/137 , A61K2300/00
-
6.发明公开PHARMACEUTICAL COMPOSITE FORMULATION COMPRISING HMG-COA REDUCTASE INHIBITOR AND ASPIRIN 审中-公开与HMG-CoA还原酶和阿司匹林药物复合制剂
公开(公告)号：EP2651401A2
公开(公告)日：2013-10-23
申请号：EP11848595.2
申请日：2011-12-14
发明人： KIM, Yong Il , NA, Young Jun , CHOI , Jun Young , KIM, Min Jung , WOO, Jong Soo , PARK, Jae Hyun
CPC分类号： A61K9/16 , A61K9/1611 , A61K9/1676 , A61K9/4808 , A61K9/5042 , A61K9/5047 , A61K9/5078 , A61K9/5084 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/47 , A61K31/505 , A61K31/616 , A61K45/06 , G01N33/15 , A61K2300/00
摘要： Provided is a pharmaceutical composite formulation for preventing or treating cardiovascular diseases, which comprises (1) a first particle comprising an HMG-CoA reductase inhibitor and a basic additive; and (2) a second particle comprising a core containing aspirin and an enteric coating layer coated on said core, wherein the difference in the average diameters of said first and second particles is 100 μm to 800 μm; a method for preparing same; and a method of validating the quality of same. The pharmaceutical composite formulation according to the present invention can improve the stability of an active ingredient and prevent adverse impacts between the active ingredients to thereby enable an accurate quality validation of the pharmaceutical composite formulation.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.011 秒)
